VZV encephalitis that developed in an immunized patient during fingolimod therapy

Neurology

Volumn 84, Issue 1, 2015, Pages 99-100

  Issa, Naoum P ^a   Hentati, Afif ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ACETYLSALICYLIC ACID; ACICLOVIR; ETIRACETAM; FINGOLIMOD; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE; VARICELLA ZOSTER VACCINE;

AGED; BRAIN INFARCTION; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER ENCEPHALITIS; HUMAN; IMMUNIZATION; MULTIPLE SCLEROSIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STUTTERING; TONIC CLONIC SEIZURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; UVEITIS; VACCINATION; WHITE MATTER LESION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; IMMUNOCOMPROMISED PATIENT; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE;

ENCEPHALITIS, VARICELLA ZOSTER; FEMALE; HERPES ZOSTER VACCINE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84925935594     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001109     Document Type: Note

References (6)

1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
2. Ricklin ME, Lorscheider J, Waschbisch A, et al. T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology 2013;81:174-181.
3. Kappos L, Radue E-W, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
4. Winkelmann A, Loebermann M, Reisinger EC, Peter Hartung H, Zettl UK. Fingolimod treatment for multiple sclerosis patients what do we do with varicella? Ann Neurol 2011;70:673-674.
5. European Medicines Agency. European Public Assessment Report: Gilenya (fingolimod). London: European Medicines Agency; 2011.
6. Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011;76:1214-1221.